ArticleCancer drug resistance (Alhambra, Calif.)2021

Using cfRNA as a tool to evaluate clinical treatment outcomes in patients with metastatic lung cancers and other tumors.

Luis E Raez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.